Reckitt Benckiser talks about Mucinex, Airborne line extensions

SLOUGH, England — Reckitt Benckiser has line extended its Mucinex franchise into the year-round allergy sector with Mucinex Allergy, Heather Allen, Reckitt Benckiser EVP category development, told analysts Wednesday. 

"Super fantastic launch in the U.S.," she said. "Allergy is a $2.5 billion market in the U.S. More than 75% of Mucinex users also take an allergy treatment, and now, we're able to offer them Mucinex Allergy, maximum strength, non-drowsy antihistamine, acts fast and lasts for 24 hours."

Reckitt Benckiser is also line extending its Airborne platform with Airborne Everyday. "People take it when they feel they need a boost or they feel they need support for their immune system," Allen explained. "We're launching now Airborne Everyday, bringing immune support plus a multivitamin, because lots of Airborne users also take a multivitamin," she said. "Given we've had this business for about a year, we're really, really excited to be driving all of this innovation to market."